Amarin (AMRN) Set to Announce Earnings on Wednesday

Amarin (NASDAQ:AMRN) is set to announce its earnings results before the market opens on Wednesday, July 31st. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Amarin (NASDAQ:AMRN) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.02. The business had revenue of $56.52 million for the quarter, compared to analyst estimates of $51.34 million. Amarin had a negative return on equity of 9.48% and a negative net margin of 18.96%. During the same quarter in the previous year, the firm earned ($0.04) earnings per share. On average, analysts expect Amarin to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Amarin Stock Down 2.0 %

Shares of Amarin stock opened at $0.78 on Tuesday. The company has a 50 day moving average price of $0.76 and a 200 day moving average price of $0.93. The firm has a market capitalization of $320.32 million, a P/E ratio of -6.50 and a beta of 1.95. Amarin has a 52 week low of $0.63 and a 52 week high of $1.37.

Analyst Ratings Changes

Several research firms have recently commented on AMRN. Cantor Fitzgerald reiterated an “overweight” rating on shares of Amarin in a research note on Tuesday, June 18th. StockNews.com cut Amarin from a “buy” rating to a “hold” rating in a research report on Thursday, July 4th.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.